头孢哌酮/舒巴坦联合克拉霉素治疗慢性阻塞性肺疾病合并下呼吸道感染的疗效观察

Effect of cefoperazone/sulbactam combined with clarithromycin on chronic obstructive pulmonary disease complicated by lower respiratory tract infection

目的观察头孢哌酮/舒巴坦联合克拉霉素治疗慢性阻塞性肺疾病(COPD)合并下呼吸道感染的临床疗效。方法 2010年1月-2011年1月78例COPD合并下呼吸道感染患者,按随机数字表法分为两组,观察组39例采用头孢哌酮/舒巴坦联合克拉霉素治疗,对照组39例仅采用头孢哌酮/舒巴坦治疗,比较观察两组的临床疗效及临床症状变化。结果观察组的总有效率为94.9%,明显高于对照组的74.4%,两组比较差异有统计学意义(P<0.05);观察组的平均退热时间、白细胞恢复正常时间、肺部湿啰音消失时间及住院时间分别为(3.43±1.23)h、(5.07±1.25)d、(5.62±1.06)d和(7.82±1.51)d,对照组为(4.62±1.67)h、(6.24±1.72)d、(7.08±1.53)d和(9.68±1.82)d,两组比较差异有统计学意义(P<0.05);两组不良反应发生比较,差异无统计学意义。结论头孢哌酮/舒巴坦联合克拉霉素,治疗慢性阻塞性肺疾病合并下呼吸道感染,能够明显提高疗效,改善患者临床症状,不良反应少,值得临床推广应用。

OBJECTIVE To observe the clinical efficacy of cefoperazone/sulbactam combined with clarithromycin in the treatment of chronic obstructive pulmonary disease（COPD） complicated by lower respiratory tract infection.METHODS From Jan.2010 to Jan.2011,78 cases with COPD complicated by lower respiratory tract infection were randomly divided into two groups：39 cases in treatment group were treated with cefoperazone/sulbactam combined with clarithromycin and 39 cases in control group were treated with only cefoperazone/sulbactam.The clinical efficacy and the change of clinical symptoms were compared between the two groups.RESULTS The total effective rates in treatment group was 94.9% which was significantly higher than 74.4% in control group（P〈0.05）.The mean fever clearance,recovery time of white blood cell,moist rales clearance time and hospitalization in treatment group were（3.43±1.23）h,（5.07±1.25）days,（5.62±1.06）days and（7.82±1.51）days,respectively,and were（4.62±1.67）h,（6.24±1.72）days,（7.08±1.53）days and（9.68±1.82）days in control group,respectively.There were statistical differences between the two groups（P〈0.05）.There was no statistical difference in adverse reaction between the two groups.CONCLUSION The application of cefoperazone/sulbactam combined with clarithromycin in the treatment of COPD complicated by lower respiratory tract infection can improve the clinical efficacy and symptoms and has few adverse effect,which is worthy of promotion in clinical.